To assess the effectiveness and safety of nonsurgical repigmentation therapies in localised and generalised vitiligo by means of a meta-analysis.
Participants included in the review
From the description of the included studies given it can be inferred that the participants included were those with localised or generalised vitiligo. Localised vitiligo was defined as vitiligo affecting less than 20% of the total body surface. No other information was available regarding the participants.
Outcomes assessed in the review
The outcome assessed was repigmentation of the affected area and the various side-effects from the interventions. Treatment was regarded as successful when more than 75% repigmentation was achieved.
How were decisions on the relevance of primary studies made?
Two investigators independently assessed the studies for inclusion, and any disagreements were resolved by consultation with a third investigator.
Data extraction
The authors do not state how many of the reviewers performed the data extraction. Data were extracted for the following: number of patients in active and placebo groups, number of responders to the therapy in both the active and the placebo group, treatment duration, number of series reporting side-effects, and number of patients reporting different types of side-effects.
Methods of synthesis
How were the studies combined? A random-effects model was used to estimate the treatment effect across RCTs. Analysis on patients series was based on sample size weighted averages for each modality, by dividing the total number of patients who achieved more than 75% repigmentation by the total number of patients in the included series.
Treatment specific side-effects were estimated by dividing the number of patients with side-effects by the total number of patients studied in the patient series.
The authors do not provide any assessment of publication bias.
How were differences between studies investigated?
No formal test of heterogeneity was reported, nor an attempt made to evaluate possible causes of heterogeneity that may be present in the combined studies. However, a random-effects model was used to combine RCTs because the study population and treatment outcomes in these trials were expected to be heterogeneous.
Results of the review
For localised vitiligo: 10 RCTs (approximately 381 participants) and 29 patient series (993 participants) were included. For generalised vitiligo: 10 RCTs (approximately 366 participants) and 46 patient series (1,866 participants) were included.
1. Therapies for localised vitiligo.
The mean treatment duration varied from 5 to 8 months.
RCTs: the odds ratio (OR) showed non significant differences between class 4 corticosteroids (OR 1.00, 95% confidence interval, CI: 0.16, 6.21), intralesional corticosteroids (single study OR 1.42, 95% CI: 0.31, 6.47), topical khellin (2 to 3%) plus UV-A (OR 1.18, 95% CI: 0.38, 3.62), or topical khellin (5%) plus UV-A (OR 1.00, 95% CI: 0.39, 2.54) and their respective placebos. Class 3 corticosteroids had a significant OR (14.32, 95% CI: 2.45, 83.72) versus placebo.
Patient series: class 3 corticosteroids had 56% of patients achieving more than 75% repigmentation (95% CI: 50, 62), and class 4 corticosteroids achieved 55% (95% CI: 49, 61).
Side-effects: 97% of the patient series reported side-effects. Of the topical psoralen plus UV-A group, methoxsalen had the highest proportion of patients developing phototoxic reactions (58%, 95% CI: 51, 65), followed by trioxsalen (39%, 95% CI: 23, 56) and PS (25%, 95% CI: 12, 38). Atrophy was the most common side-effect with local corticosteroids occurring mostly in patients receiving intralesional corticosteroids (33%, 95% CI: 22, 43), followed by patients using class 4 corticosteroids (14%, 95% CI: 10, 18) and class 3 corticosteroids (2%, 95% CI: 1, 5). Other less common sideeffects were telangiectasia, corticosteroid-induced acne and hypertrichosis. Studies on topical khellin (2, 3 and 5%) plus UV-A did not report any side-effects.
Therapies for generalised vitiligo.
The mean treatment duration of photochemotherapies varied between 9 months for phenylalanine plus UV-A and 24 months for oral PS plus UV-A. The treatment with oral minipulse therapy varied between 6 and 24 months.
RCTs: ORs showed significant differences for oral methoxsalen plus sunlight (single study OR 23.37, 95% CI: 1.33, Patient series: phototherapy with narrowband UV-B had the highest percentage of patients who achieved more than 75% repigmentation (63%, 95% CI: 50, 76), followed by broadband UV-B (57%, 95% CI: 29, 82). Only one study of each was included. Oral methoxsalen plus UV-A and oral bergapten plus UV-A had success rates of 51% (95% CI: 46, 56) and 43% (95% CI: 38, 48), respectively. The differences between the mean success rates of narrowband UV-B, broadband UV-B, and oral methoxsalen plus UV-A were not significant.
Side-effects: 87% of the patient series that were included reported side-effects. Of the oral photochemotherapeutic modalities, methoxsalen had the highest proportion of patients who developed nausea and vomiting (29%, 95% CI: 24, 35), followed by khellin (9%, 95% CI: 2, 16) and PS (8%, 95% CI: 2, 15). Phototoxic reactions were seen mostly in patients taking methoxsalen (25%, 95% CI: 20, 30), followed by bergapten (6%, 95% CI: 4, 8). Abnormal results of liver function tests were observed mostly in patients using khellin (17%, 95% CI: 8, 26). Systemic reactions (headache, dizziness) were reported mostly in patients taking oral PS (24%, 95% CI: 14, 33). Pruritus was most frequently seen with the use of methoxsalen (31%, 95% CI: 26, 37). An increased contrast between normal and depigmented skin was reported mostly with the use of methoxsalen (10%, 95% CI: 6, 13). In comparison with daily intake of corticosteroids, oral minipulse therapy with corticosteroids was associated with a lower mean proportion of patients with systemic and cutaneous side-effects.
